
|Articles|July 1, 2004
FDA allows four firms to make generic solution
Washington, DC-Four manufacturers of ocular products have received FDA approval to market ofloxacin ophthalmic solution 0.3%, a generic version of Allergan Inc.'s Ocuflox, for the treatment of certain strains of bacteria in conjunctivitis and corneal ulcers.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
Ocular pickleball injuries rise sharply with increasing game popularity
3
AAO 2025: The evolution of eye care on display at AAO 2025
4
AAO 2025: Which lens to consider in patients with pseudoexfoliation
5